{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:24:12Z","timestamp":1649006652597},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","interventional.theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.iccl.2016.06.008","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T09:39:41Z","timestamp":1470908381000},"page":"497-511","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Controversies in the Management of ST Elevation Myocardial Infarction"],"prefix":"10.1016","volume":"5","author":[{"given":"Neeraj","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"43","key":"10.1016\/j.iccl.2016.06.008_bib1","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1021\/bi00107a001","article-title":"The coagulation cascade: initiation, maintenance, and regulation","volume":"30","author":"Davie","year":"1991","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.iccl.2016.06.008_bib2","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.iccl.2016.06.008_bib3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.iccl.2016.06.008_bib4","first-page":"80","article-title":"Anticoagulant therapy for percutaneous coronary intervention","volume":"3","author":"Rao","year":"2010","journal-title":"Circulation"},{"issue":"1S","key":"10.1016\/j.iccl.2016.06.008_bib5","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.iccl.2016.06.008_bib6","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0002-9149(03)00159-0","article-title":"Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations","volume":"91","author":"Cho","year":"2003","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2016.06.008_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1213\/00000539-200302000-00015","article-title":"Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass","volume":"96","author":"Koster","year":"2003","journal-title":"Anesth Analg"},{"issue":"21","key":"10.1016\/j.iccl.2016.06.008_bib8","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9784","key":"10.1016\/j.iccl.2016.06.008_bib9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.iccl.2016.06.008_bib10","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.iccl.2016.06.008_bib11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/eurheartj\/ehu214","article-title":"Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial","volume":"35","author":"Zeymer","year":"2014","journal-title":"Eur Heart J"},{"issue":"9957","key":"10.1016\/j.iccl.2016.06.008_bib12","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.iccl.2016.06.008_bib13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.iccl.2016.06.008_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","volume":"35","author":"Schulz","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.iccl.2016.06.008_bib15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2016.06.008_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2015.10.006","article-title":"An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention","volume":"171","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.iccl.2016.06.008_bib17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.jacc.2010.02.005","article-title":"Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry","volume":"55","author":"Peterson","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.iccl.2016.06.008_bib18","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.iccl.2016.06.008_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2013.09.027","article-title":"Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: the HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2016.06.008_bib20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.amjcard.2016.01.015","article-title":"Meta-analysis of effects of bivalirudin versus heparin on myocardial ischemic and bleeding outcomes after percutaneous coronary intervention","volume":"117","author":"Barria Perez","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.06.008_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2016.01.206","article-title":"Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials","volume":"209","author":"Zhang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.iccl.2016.06.008_bib22","first-page":"e002789","article-title":"Factors affecting bleeding and stent thrombosis in clinical trials comparing bivalirudin with heparin during percutaneous coronary intervention","volume":"8","author":"Bittl","year":"2015","journal-title":"Circulation"},{"issue":"9943","key":"10.1016\/j.iccl.2016.06.008_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.06.008_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2016.02.131","article-title":"Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial","volume":"211","author":"Kilic","year":"2016","journal-title":"Int J Cardiol"},{"issue":"15","key":"10.1016\/j.iccl.2016.06.008_bib25","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.iccl.2016.06.008_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"16","key":"10.1016\/j.iccl.2016.06.008_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.110.981688","article-title":"Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction","volume":"123","author":"Dangas","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.iccl.2016.06.008_bib28","first-page":"171","article-title":"Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention","volume":"4","author":"Kimmelstiel","year":"2011","journal-title":"Circulation"},{"issue":"1 Pt B","key":"10.1016\/j.iccl.2016.06.008_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcin.2014.11.002","article-title":"Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)","volume":"8","author":"Clemmensen","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.06.008_bib30","doi-asserted-by":"crossref","first-page":"e001593","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2016.06.008_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","article-title":"Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])","volume":"8","author":"White","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"9792","key":"10.1016\/j.iccl.2016.06.008_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.iccl.2016.06.008_bib33","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/j.1538-7836.2011.04445.x","article-title":"Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis","volume":"9","author":"Navarese","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.06.008_bib34","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis","volume":"344","author":"Silvain","year":"2012","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.iccl.2016.06.008_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.iccl.2016.06.008_bib36","first-page":"305","article-title":"New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications","volume":"4","author":"McCann","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"10.1016\/j.iccl.2016.06.008_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/euhj.2001.2940","article-title":"Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction","volume":"23","author":"Baird","year":"2002","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2016.06.008_bib38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/hc3101.093866","article-title":"Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)","volume":"104","author":"Ross","year":"2001","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.iccl.2016.06.008_bib39","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"issue":"9282","key":"10.1016\/j.iccl.2016.06.008_bib40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction","volume":"358","author":"Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iccl.2016.06.008_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"Wallentin","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.iccl.2016.06.008_bib42","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.iccl.2016.06.008_bib43","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A\u00a0synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.iccl.2016.06.008_bib44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0735-1097(98)00138-7","volume":"31","author":"Metz","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2016.06.008_bib45","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0735-1097(99)00319-8","article-title":"Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial","volume":"34","author":"Neuhaus","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.iccl.2016.06.008_bib46","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion\/Occlusion (HERO) Trial Investigators","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"issue":"9296","key":"10.1016\/j.iccl.2016.06.008_bib47","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","article-title":"Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial","volume":"358","author":"White","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iccl.2016.06.008_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.iccl.2016.06.008_bib49","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0735-1097(03)01040-4","article-title":"The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial","volume":"42","author":"Cohen","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T08:58:16Z","timestamp":1536483496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745816300633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2211745816300633"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2016.06.008","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the Management of ST Elevation Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2016.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}